Detail

Study ID: Washington University CACTUX Trial

Title:

Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients with Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)

Description:
Title: Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients with Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) Description: The purpose of this research study is to look at the effect of a treatment regimen called CACTUX on head and neck cancer. The CACTUX regimen is a combination of three drugs called cisplatin, nab-paclitaxel, and cetuximab (although carboplatin may be given in place of cisplatin if participants have previously had problems receiving cisplatin). The use of nab-paclitaxel in this combination is different from routine care, in which a drug called 5FU is often given instead, but the investigators group has conducted previous research where the investigators incorporated nab-paclitaxel into routine treatment with cisplatin, 5FU, and cetuximab. The investigators are looking at the incidence of side effects with the CACTUX regimen as well as response of the disease and health status. 4 Key Inclusion/Exclusion Criteria including Age Range, if applicable: 1. Incurable Head and Neck squamous cell carcinoma which may be metastatic, a local or regional recurrence in a previously irradiated site that is unresectable or the patient has declined resection 2. Disease (cancer) that can be measured in at least one dimension on CT scan 3. At least 4 months since completion of any previous therapy 4. No history of other cancer in the past 2 years or known brain metastases
Location:
Sioux Falls Region
Principal Investigator:
Steven Powell, MD
Disease:
Head and Neck
Stage:
Unknown
Status:
Active - Open to Accrual